A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Launched by TARGET PHARMASOLUTIONS, INC. · Nov 1, 2016
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The TARGET-HCC study is a research project that focuses on understanding how patients with hepatocellular cancer (HCC) are treated and managed in real-life situations. This study aims to collect information from a diverse group of patients across different healthcare settings to learn more about the safety and effectiveness of various treatments for HCC. By doing this, researchers hope to improve care for future patients with this condition.
To participate in this study, patients need to be at least 18 years old and have a diagnosis of HCC, whether it's confirmed through tissue samples or imaging tests. Both men and women are welcome to join, including those who are receiving treatment or those who are being monitored without specific therapy. Participants can expect to share their health information over time, which will help researchers better understand how HCC affects individuals and how different treatments work in everyday practice. It's important to note that patients who cannot provide written consent are not eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female patients, age ≥18 years
- • 2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included)
- Exclusion Criteria:
- • 1. Inability to provide written informed consent
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Ann Arbor, Michigan, United States
Philadelphia, Pennsylvania, United States
New York, New York, United States
Charleston, South Carolina, United States
Chicago, Illinois, United States
Charlottesville, Virginia, United States
Baltimore, Maryland, United States
Iowa City, Iowa, United States
Boston, Massachusetts, United States
Seattle, Washington, United States
Chicago, Illinois, United States
Detroit, Michigan, United States
New Orleans, Louisiana, United States
Palo Alto, California, United States
Omaha, Nebraska, United States
Little Rock, Arkansas, United States
Washington, District Of Columbia, United States
Chapel Hill, North Carolina, United States
Richmond, Virginia, United States
Atlanta, Georgia, United States
Leipzig, , Germany
Atlanta, Georgia, United States
Hershey, Pennsylvania, United States
San Francisco, California, United States
Hannover, , Germany
Saint Louis, Missouri, United States
Düsseldorf, , Germany
Sacramento, California, United States
Sevilla, , Spain
Hannover, , Germany
Santander, , Spain
New York, New York, United States
Magdeburg, , Germany
Madrid, , Spain
Sevilla, , Spain
Frankfurt, , Germany
Aachen, , Germany
Berlin, , Germany
Coruña, , Spain
Atlanta, Georgia, United States
Pamplona, , Spain
Wenatchee, Washington, United States
New Brunswick, New Jersey, United States
Milan, , Italy
Houston, Texas, United States
Omaha, Nebraska, United States
New York, New York, United States
Los Angeles, California, United States
San Francisco, California, United States
Mainz, , Germany
Tampa, Florida, United States
Phoenix, Arizona, United States
Pasadena, California, United States
Gainesville, Florida, United States
Miami, Florida, United States
Richmond, Virginia, United States
Clearwater, Florida, United States
Charlotte, North Carolina, United States
Madison, Wisconsin, United States
Baltimore, Maryland, United States
Palo Alto, California, United States
Jacksonville, Florida, United States
Chicago, Illinois, United States
Jackson, Mississippi, United States
Manhasset, New York, United States
Portland, Oregon, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Nice, , France
Paris, , France
Palermo, , Italy
Rozzano, , Italy
San Giovanni Rotondo, , Italy
Valencia, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials